By activating both GIP and GLP-1 receptors, Mounjaro enhances insulin secretion in response to meals, suppresses glucagon release, slows gastric emptying, and reduces appetiteleading to improved glycaemic control and weight reduction
Release it slowly down the vial's inner wall to limit foaming
The American Diabetes Association (ADA) Standards of Care and American College of Physicians (ACP) guidelines support the use of GLP-1 receptor agonists, including dual agonists like tirzepatide, as effective options for glycemic control and weight management
To help people figure out who qualifies, whats involved and what to expect for first-time GLP-1 users, a pair of weight management specialists at MUSC Health sat down for this Q&A
As of 2026, with improved regulatory clarity and access through licensed providers, these peptides are becoming more structured, safer, and clinically accessible but should always be used under professional guidance.